Objectives: Ceftaroline and ceftobiprole are new cephalosporins, which are active against MRSA by inhibiting PBP2a. Recently, high rates of resistance to ceftaroline were reported from Ghana. The objective of this study was to assess rates of resistance to ceftaroline and ceftobiprole in MRSA from Africa and to describe potential missense mutations of PBP2a.
Introduction
Ceftaroline and ceftobiprole are recently introduced cephalosporins, which are active against MRSA. Ceftaroline causes an allosteric change of PBP2a so that a second molecule can bind to the now exposed active site. 1 Ceftobiprole can access the active site of PBP2a through its residue R2. 2 Ceftaroline and ceftobiprole are approved for the treatment of skin and soft tissue infection. Ceftaroline non-susceptibility (including resistant and intermediate isolates) ranges between 3.9% and 33.5% among MRSA isolates worldwide. 3, 4 In industrialized countries, ceftaroline nonsusceptibility is associated with certain MRSA lineages (e.g. ST228, ST247 and ST239) and missense mutations in PBP2a (e.g. N146K, E150K and N204K). 5, 6 The resistance to ceftobiprole can be associated with the E447K mutation in PBP2a. 2 A recent study from Ghana reported a high rate of resistance to ceftaroline among MRSA (20%), which predominantly belonged to ST247. 7 This finding cannot be linked directly to the use of ceftaroline as this drug is not distributed in Ghana. 7 Apart from the report by Egyir et al., 7 no data on the resistance rates and underlying pattern of missense mutations are available for the new anti-MRSA cephalosporins in sub-Saharan Africa. Data on resistances to newer, MRSA-active compounds are particularly important as MRSA rates among Staphylococcus aureus from clinical infection seem to be on the increase in many African countries. 8 Therefore, the objectives of this study were to assess the rates of resistance to ceftaroline and ceftobiprole in a collection of MRSA isolates from Africa, to detect potential missense mutations in PBP2a and to identify clonal lineages associated with anti-MRSA cephalosporin resistance.
Materials and methods

Bacterial isolates
The MRSA isolates (n¼60) derived from studies on S. aureus colonization (n ¼37) and infection (n¼23) and were collected in Cô te d'Ivoire (n¼17, in 2012), DR Congo (n ¼ 6, in 2011 -13), Gabon (n ¼ 21, in 2009 -13) and Nigeria (n ¼ 16, in 2007 -12). 9 -14 All isolates were spa and SCCmec typed, and MLST was performed particularly for one isolate per spa type per study. 15, 16 The lukS-PV/lukF-PV gene encoding the Panton -Valentine leucocidin was detected by PCR. 17 Antimicrobial susceptibility testing 
mecA sequencing
Genomic DNA was extracted with QiAamp according to the manufacturer's instructions (Qiagen, Hilden, Germany). The mecA gene was amplified using a previously published forward primer and a newly designed reverse primer (MecA_Seq R 5 ′ -ACCTTCTACACCTCCATATCAC-3 ′ ). 6 The amplicon (2190 bp) was sequenced using several nested primers:
. Sequences were aligned with MUSCLE as implemented in Mega 6 (www.megasoftware.net) using the mecA reference sequences of N315 (SA0038) and strain 4977 (JQ58212), which displays four missense mutations of mecA (N146K, E150K, N204K, G246E). 18 The GenBank accession numbers of the detected mutant types are KR936059-KR936061.
Statistical analysis
MIC 50 and MIC 90 were calculated as the 50th and 90th percentiles of the MIC values. The correlation between MICs of ceftaroline and ceftobiprole was tested with Pearson's correlation coefficient. MICs from Etest were rounded to the next doubling dilution step for comparison of the MICs between Etest and microdilution. The significance level was set at 0.05. All analyses were performed with 'R' (https://cran.r-project.org, Version 2.13.1).
Results
In total, 16.7% (n¼ 10) and 15% (n¼9) of isolates were resistant to ceftaroline and ceftobiprole, respectively, according to the broth microdilution method. The correspondent MICs of ceftaroline and ceftobiprole correlated significantly [r ¼ 0.92 (95% CI 0.87-0.95), P,0.001; Figure 1 ].
The proportion of resistant isolates as determined by Etest was 10% (n¼ 6) and 15% (n¼ 9) for ceftaroline and ceftobiprole, respectively. There was a trend for lower MICs by Etest compared with microdilution, which resulted in four very major errors and a 93.3% categorical agreement (Table S1 , available as Supplementary data at JAC Online) for ceftaroline. In contrast, the categorical agreement between Etest and microdilution was 100% for ceftobiprole.
In total, 28 isolates had a WT PBP2a amino acid sequence and belonged to ST5, ST8 and ST88. These isolates were predominantly found in Cô te d'Ivoire and Gabon (Table 1 ). All were susceptible to ceftaroline and ceftobiprole.
Isolates displaying the combination of three missense mutations of PBP2a (N146K -N204K -G246E) were solely detected in Isolates with mecA WT and G246E and S225R mutations form a cluster within the susceptibility ranges (area shaded grey). In contrast, the majority of the N146K -N204K -G246E triple mecA mutants cluster outside the susceptibility ranges for ceftaroline and ceftobiprole. Schaumburg et al.
Nigeria between 2007 and 2013 and belonged to ST15 (n¼ 1) and ST241 (n ¼ 10), which both cluster in the MLST clonal complex, CC5. Resistance rates were high in this group for ceftaroline (90.9%, n ¼ 10) and ceftobiprole (81.8%, n ¼ 9). Noteworthy, all but one isolates (ST241) were resistant to ceftaroline and ceftobiprole. Triple mutants also had markedly higher MICs of cefoxitin compared with isolates carrying the WT mecA or single mutations (Table S2 ). This was confirmed by a gradient diffusion method, which covers a broader concentration range (MIC 50 .256 mg/L versus MIC 50 96 mg/L, respectively).
Isolates that harboured either the S225R (n ¼ 11) or G246E (n ¼ 10) missense mutation were fully susceptible to ceftaroline and ceftobiprole.
All Table S2 ). Three isolates (5%) were resistant to rifampicin.
Discussion
We analysed resistance rates and the MICs for African MRSA isolates of new cephalosporins ceftaroline and ceftobiprole. The main findings are high rates of resistance to both agents in a clone belonging to ST241, which were associated with a combination of three missense mutations of PBP2a (N146K -N204K-G246E).
Overall, the ceftaroline resistance rate in our MRSA collection from four African countries (Cô te d'Ivoire, DR Congo, Gabon, Nigeria) is similar to the resistance rates reported from Ghana based on broth microdilution (20%), but was markedly higher compared with large MRSA collections from Europe (0.05%-4.5%). 5, 7, 19 Similarly, ceftobiprole resistance was also higher in our collection (15%) compared with a large study from Europe, Turkey and Israel (1.7%). 20 In contrast to our findings, ceftaroline resistance was not associated with ceftobiprole resistance in the report from Ghana. 7 It is possible that the isolates in our study have different PBP2a mutations compared with Ghanaian MRSA. One might also speculate, that ST241 MRSA harbour mutations in additional genes, which might mediate resistance to ceftobiprole (i.e. pbp4, gdpP).
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Our data demonstrate an underestimation of ceftaroline MIC and high rate of very major errors using the Etest method. Similarly, Strommenger et al. 5 have also reported generally lower Etest MICs compared with broth microdilution results.
We detected four different missense mutations; three of them have been reported from other countries: N146K (Germany, Greece, Spain, Switzerland, Thailand), N204 (Germany, Thailand) and G246E (Germany, Thailand, Switzerland). 6, 18, 19 To the best of our knowledge, the S225R missense mutation has not been reported yet, but seems to be present in West and Central Africa (Table 1) . However, this mutation does not interfere with ceftaroline or ceftobiprole binding to PBP2a, as all isolates carrying this mutation were susceptible to these agents.
In contrast, the combined mutation N146K -N204K -G246E was associated with high rates of resistance to ceftaroline (90.9%) and ceftobiprole (81.8%). However, as not all isolates with this triple mutation were resistant, one might argue that additional mutations in other genes are necessary to mediate full resistance. 2 The N146K mutation is located in the non-penicillin binding domain of PBP2a and confers resistance to ceftaroline through an alteration of the salt bridge network at the allosteric site. 1 Binding of ceftaroline to this allosteric site causes a conformational change in the WT, which enhances access of a second molecule to the active site.
1 While N146K is associated with MICs in the range 1 -2 mg/L (ceftaroline) and 2 -4 mg/L (ceftobiprole), other mutations such as Y446N and E447K are required for high-level resistance to ceftaroline (MIC .32 mg/L).
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N146K was always co-detected with G246E, but G246E does not seem to confer resistance to ceftaroline or ceftobiprole as single mutants of G246E had MICs within the susceptibility range (Table 1) .
In our study, resistance to ceftaroline and ceftobiprole was only found in isolates belonging to ST241 and ST15 (Table 1) . To the best of our knowledge, resistance to 'fifth-generation cephalosporins' in these clones has not been described outside of Africa yet. In contrast, ceftaroline-resistant MRSA was mostly found in isolates belonging to ST228 and ST239 in Germany, Switzerland, Spain and Thailand. 5, 6 The triple mutation (N146K -N204K -G246E) seems to have a selective advantage towards cefoxitin as the MIC of cefoxitin was markedly higher in triple mutants compared with other isolates without this mutation pattern (Table S2) .
A few limitations of this study need to be addressed: First, we were unable to perform SCCmec typing, as only two of 60 isolates were typeable. Second, the sample size was too small to draw a clear epidemiological picture of the distribution of ceftaroline-and ceftobiprole-resistant ST241 MRSA in Africa. It is possible that we will underestimate the resistance rates, as the ST239/ST241 MRSA lineage is widespread in North and West Africa. 22 In conclusion, resistance to ceftaroline and ceftobiprole in Africa is associated with ST241 and the triple mutation N146K -N204K-G246E.
